Cargando…
Update on omicron variant: What we know so far
The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012418/ https://www.ncbi.nlm.nih.gov/pubmed/35343206 http://dx.doi.org/10.4103/ijp.ijp_955_21 |
_version_ | 1784687792144515072 |
---|---|
author | Choudhary, Gajendra Prajapat, Manisha Kumaravel, J Prabha, Praisy K Sarma, Phulen Handa, Vrishbhanu Kaur, Harminder Patel, Ajay Prakash Medhi, Bikash |
author_facet | Choudhary, Gajendra Prajapat, Manisha Kumaravel, J Prabha, Praisy K Sarma, Phulen Handa, Vrishbhanu Kaur, Harminder Patel, Ajay Prakash Medhi, Bikash |
author_sort | Choudhary, Gajendra |
collection | PubMed |
description | The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals. |
format | Online Article Text |
id | pubmed-9012418 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90124182022-04-16 Update on omicron variant: What we know so far Choudhary, Gajendra Prajapat, Manisha Kumaravel, J Prabha, Praisy K Sarma, Phulen Handa, Vrishbhanu Kaur, Harminder Patel, Ajay Prakash Medhi, Bikash Indian J Pharmacol Short Communication The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals. Wolters Kluwer - Medknow 2022 2022-03-18 /pmc/articles/PMC9012418/ /pubmed/35343206 http://dx.doi.org/10.4103/ijp.ijp_955_21 Text en Copyright: © 2022 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Short Communication Choudhary, Gajendra Prajapat, Manisha Kumaravel, J Prabha, Praisy K Sarma, Phulen Handa, Vrishbhanu Kaur, Harminder Patel, Ajay Prakash Medhi, Bikash Update on omicron variant: What we know so far |
title | Update on omicron variant: What we know so far |
title_full | Update on omicron variant: What we know so far |
title_fullStr | Update on omicron variant: What we know so far |
title_full_unstemmed | Update on omicron variant: What we know so far |
title_short | Update on omicron variant: What we know so far |
title_sort | update on omicron variant: what we know so far |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012418/ https://www.ncbi.nlm.nih.gov/pubmed/35343206 http://dx.doi.org/10.4103/ijp.ijp_955_21 |
work_keys_str_mv | AT choudharygajendra updateonomicronvariantwhatweknowsofar AT prajapatmanisha updateonomicronvariantwhatweknowsofar AT kumaravelj updateonomicronvariantwhatweknowsofar AT prabhapraisyk updateonomicronvariantwhatweknowsofar AT sarmaphulen updateonomicronvariantwhatweknowsofar AT handavrishbhanu updateonomicronvariantwhatweknowsofar AT kaurharminder updateonomicronvariantwhatweknowsofar AT patelajayprakash updateonomicronvariantwhatweknowsofar AT medhibikash updateonomicronvariantwhatweknowsofar |